Dermatology Payer Portal Automation: Streamlining PA for Biologics & Mohs

Klivira provides advanced dermatology payer portal automation, transforming the manual, time-intensive process of securing prior authorizations for critical treatments like biologics and Mohs surgery.

For revenue cycle directors and prior authorization coordinators in dermatology, navigating diverse payer portals for PA submissions is a significant operational challenge. This manual burden often leads to delays, errors, and staff burnout, directly impacting patient access to essential skin care therapies. Klivira's automation layer is designed to address these specific workflow inefficiencies.

The Unique Prior Authorization Landscape in Dermatology

Dermatology practices face a high volume of prior authorizations, particularly for high-cost biologics used in conditions like psoriasis and atopic dermatitis, and for specialized procedures such as Mohs micrographic surgery. These PAs are often complex, requiring detailed clinical documentation and adherence to specific step-therapy protocols, adding significant administrative overhead to care delivery.

Common PA Triggers and Documentation in Dermatology

Biologics for psoriasis (e.g., adalimumab, secukinumab, guselkumab, risankizumab) and atopic dermatitis (e.g., dupilumab, tralokinumab), requiring documentation of disease severity (PASI, BSA, EASI scores) and prior therapy trials (topicals, phototherapy, conventional systemics).
Hidradenitis suppurativa biologics (e.g., adalimumab, secukinumab), with specific diagnostic and treatment history requirements.
Mohs micrographic surgery, especially for non-melanoma skin cancers in cosmetically or functionally sensitive areas, necessitating adherence to AAD Appropriate Use Criteria.
Advanced skin cancer treatments and certain phototherapy regimens, where payer policies often mandate specific clinical pathways or trials of less intensive therapies.

The Challenge of Manual Payer Portal Workflows in Dermatology

A significant fraction of payers, including many regional and specialty benefit managers, still rely on manual web portals for prior authorization submissions, lacking modern API integrations. For dermatology practices, this means PA coordinators must repeatedly log into disparate portals, manually transcribe patient data from EMRs, upload clinical attachments, and check status updates—a process prone to transcription errors, delays, and staff fatigue.

Klivira's Approach to Dermatology Payer Portal Automation

Klivira addresses these challenges with a robust payer portal automation layer that operates headless-browser sessions against non-API-enabled payer portals. Our system employs per-payer adapters to navigate unique portal interfaces, ensuring accurate data submission, automated attachment uploads, and efficient status monitoring. This capability is critical for dermatological PAs, which often involve complex clinical details and frequent re-authorizations.

Streamlined Workflows for Dermatology Prior Authorizations

**Automated Data Flow**: Patient demographics and clinical context are automatically transferred from your EMR to payer portals, eliminating manual data entry and reducing transcription errors for biologics and procedures.
**Guideline-Aware Submission**: The platform incorporates logic for AAD-guideline-aware step-therapy for psoriasis and atopic dermatitis biologics, and AUC validation for Mohs surgery, ensuring submissions align with common payer requirements.
**Efficient Re-authorization**: Supports periodic re-authorization cycles common for chronic biologic treatments by automating the submission of updated clinical documentation.
**Adaptive Payer Connectivity**: Klivira's routing engine intelligently selects the optimal submission channel, preferring API-based methods (Da Vinci PAS, X12 278) when available and seamlessly falling back to portal automation for other payers.
**Future-Proof Architecture**: Designed to transition as payers implement FHIR-based Prior Authorization APIs, aligning with the CMS-0057-F mandate for January 2027.

Frequently asked questions

Which specific dermatology treatments benefit most from payer portal automation?

Dermatology payer portal automation is most impactful for high-volume, complex prior authorizations. This includes biologics for psoriasis (e.g., Dupixent, Cosentyx, Tremfya, Skyrizi), atopic dermatitis, and hidradenitis suppurativa, as well as Mohs micrographic surgery. These often involve extensive documentation and frequent re-authorizations, making them ideal candidates for automated submission.

How does Klivira handle the diverse documentation requirements for dermatology PAs?

Klivira's platform is designed to process and submit the specific documentation required for dermatology PAs. This includes integrating clinical data from EMRs for elements like PASI, EASI, and BSA scores, prior topical or systemic therapy trials, and TB/hepatitis screenings for biologics. For Mohs surgery, the system helps ensure submissions align with AAD Appropriate Use Criteria.

Can Klivira's automation address the "medical vs. pharmacy benefit" distinction for dermatology drugs?

Yes, Klivira's platform is configured to handle the routing complexities associated with dermatology drugs, including differentiating between medical and pharmacy benefits. This ensures that prior authorizations for self-injected home biologics or clinic-administered infusions are directed through the correct payer channels, reducing delays and potential denials.

What happens if a payer portal changes its layout or submission process?

Klivira maintains a library of per-payer adapters that are continuously updated to reflect changes in payer portal interfaces. When a payer modifies their portal, Klivira's team updates the corresponding adapter, ensuring that your prior authorization workflows remain uninterrupted. This resilience is a core component of our payer portal automation strategy.

How does Klivira's payer portal automation fit into the broader shift towards API-based prior authorization?

Klivira views payer portal automation as a transitional yet critical layer. While our system prioritizes API integrations (like Da Vinci PAS or X12 278) where available, it seamlessly falls back to portal automation for payers without API capabilities. This strategy ensures continuity of service and positions practices for the industry-wide migration to FHIR-based Prior Authorization APIs mandated by CMS-0057-F by January 2027.